Low-dose Aspirin Therapy for Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

Low-dose Aspirin Therapy for Stage II-III Esophageal Cancer- A Multi-Center, Open Label, Randomized Controlled Phase III Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02326779
• Other study ID #: NNSFC 81302455
• Status: Withdrawn
• Phase: Phase 3
• Start date: March 2016
• Est. completion date: December 2018

Study information

• Verified date: April 2021
• Source: Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the survival benefit of low-dose aspirin use for stage II-III esophageal cancer patients.

Description:

The investigators aimed to evaluate the hypothesis that low-dose aspirin can improve survival in stage II-III esophageal cancer patients, and to evaluate whether this effect is influenced by PIK3CA, KRAS, BRAF mutation and COX-2 expression. Eligible participants will be randomized to either aspirin treatment arm (100 mg aspirin OD for 3 years), or non-aspirin user arm in 1:1 ratio. After randomization, participants will receive 3 monthly assessments during treatment and follow-up.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects with an age of 18 years or older.

2. Subjects with Stage II-III histological proven esophageal cancer.

3. Subjects with performance status (PS) of 0-1 or ECOG performance status 0-2.

4. Subjects must have signed an approved informed consent prior to any study procedures.

5. Subjects with adequate bone marrow, hepatic and renal functions, with a) neutrophils = 1.5x109/ L; platelets = 100x109/L; hemoglobin = 9g/dL; b) Total bilirubin = 2.0 x the upper limit normal; ALT and AST = 2.5 x ULN (= 5 x ULN in case of liver metastasis); c) creatinine clearance > 50 ml/min;

6. Subjects undergone complete resection of primary tumor;

7. Subjects with life expectancy = 3 months.

8. Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy )

9. Within 120 days of completion of standard therapy (surgery, chemotherapy ± radiotherapy)

Exclusion Criteria:

1. Subjects with haemorrhagic diathesis (i.e. haemophilia).

2. Subjects with prior malignant tumors except for esophageal cancers in the past 5 years.

3. Subjects with documented or suspected central nervous system metastases.

4. Subjects with serious, nonhealing wound, ulcer, or bone fracture.

5. Subjects with a history of stroke, coronary arterial disease, angina, or vascular disease.

6. Subjects who are pregnant, lactating, or not using adequate contraception.

7. Subjects who have known allergy to NSAID or Aspirin.

8. Subjects receiving other antiplatelet agents (i.e. clopidogrel, ticlopidine) or anticoagulants (i.e. warfarin, low molecular weight heparins).

9. Subjects receiving current long term treatment (= 1 month) with Aspirin or other NSAIDs.

10. Subject unwilling or unable to comply with study requirements.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• Acetylsalicylic acid
Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		5 years
Primary	Overall survival		5 years
Secondary	Adverse events		5 years